Nadarajan Tamilarasu

Title: Nadarajan Tamilarasu: Innovator in Angiogenesis Inhibition

Introduction

Nadarajan Tamilarasu is a prominent inventor based in Edison, NJ (US), known for his significant contributions to the field of medicinal chemistry. He holds a total of six patents, focusing primarily on compounds that inhibit angiogenesis, which is crucial in the treatment of various diseases, including cancer.

Latest Patents

Among his latest patents, Tamilarasu has developed tetracyclic carboline derivatives that are effective in inhibiting the expression of VEGF (Vascular Endothelial Growth Factor) post-transcriptionally. These compounds are designed for use in the treatment of conditions such as cancer, diabetic retinopathy, and exudative macular degeneration. Another notable patent involves carboline derivatives that also inhibit VEGF production, contributing to the treatment of solid tumor cancers and reducing plasma and tumor VEGF levels.

Career Highlights

Tamilarasu is currently associated with PTC Therapeutics, Inc., where he continues to innovate and develop new therapeutic solutions. His work has been instrumental in advancing the understanding of angiogenesis and its implications in various medical conditions.

Collaborations

He has collaborated with notable colleagues, including Young-Choon Moon and Soongyu Choi, to further enhance the research and development of his patented compounds.

Conclusion

Nadarajan Tamilarasu's innovative work in the field of angiogenesis inhibition showcases his commitment to advancing medical science. His contributions are paving the way for new treatments that could significantly impact patient care.